Medivation collaborated with Astellas to develop enzalutamide, a possible cure for some types of cancers like breast and prostate cancers. The US Food and Drug Administration approved XTANDI® (enzalutamide) on August 31, 2012.
Medivation has a straightforward business strategy. Beginning with a portfolio of up to six product candidates with potential of being in the clinical development stage within one year to 18 months after acquisition, Medivation will conduct the needed clinical studies internally. The development would be as rapid and as efficient as possible. Any successful development would be sold to large pharmaceutical, biotechnology or medical device company at the latest stage of clinical studies for commercialization. Recent years have proven that this business model works wonders for Medivation.